Search research articles
Contact Us
Filters
Showing results (81-90 of 105) with videos related to
Page
of 11
Sort By:
Journal of the American Academy of Dermatology
|
April 27, 2024
Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study
Ahmed Bagit, Khalad Maliyar, Mark Mansour, et al.
Journal of the American Academy of Dermatology
|
May 23, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD Study
Jennifer Soung, Yong Cui, Robert Bissonnette, et al.
JAMA Dermatology
|
August 4, 2021
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
Andrew Blauvelt, Henrique D Teixeira, Eric L Simpson, et al.
The Journal of Dermatological Treatment
|
May 11, 2026
Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials
Eric L Simpson, Vimal H Prajapati, Christopher G Bunick, et al.
Dermatology and Therapy
|
December 14, 2021
Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line
Bruce Strober, Joyce Leman, Maja Mockenhaupt, et al.
The British Journal of Dermatology
|
December 21, 2024
Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study
Vimal H Prajapati, Marieke M B Seyger, Dagmar Wilsmann-Theis, et al.
Pediatric Dermatology
|
March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)
Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.
Journal of Cutaneous Medicine and Surgery
|
September 3, 2024
Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort Study
Ahmed Bagit, Khalad Maliyar, Mark Mansour, et al.
Dermatology and Therapy
|
February 12, 2026
Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 Studies
Andrew Blauvelt, Leon Kircik, Eric L Simpson, et al.
Dermatology and Therapy
|
July 6, 2023
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
Kim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 105) with videos related to
Sort By:
Page
of 11
Journal of the American Academy of Dermatology
|
April 27, 2024
Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study
Ahmed Bagit, Khalad Maliyar, Mark Mansour, et al.
Journal of the American Academy of Dermatology
|
May 23, 2026
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD Study
Jennifer Soung, Yong Cui, Robert Bissonnette, et al.
JAMA Dermatology
|
August 4, 2021
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
Andrew Blauvelt, Henrique D Teixeira, Eric L Simpson, et al.
The Journal of Dermatological Treatment
|
May 11, 2026
Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials
Eric L Simpson, Vimal H Prajapati, Christopher G Bunick, et al.
Dermatology and Therapy
|
December 14, 2021
Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line
Bruce Strober, Joyce Leman, Maja Mockenhaupt, et al.
The British Journal of Dermatology
|
December 21, 2024
Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study
Vimal H Prajapati, Marieke M B Seyger, Dagmar Wilsmann-Theis, et al.
Pediatric Dermatology
|
March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)
Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.
Journal of Cutaneous Medicine and Surgery
|
September 3, 2024
Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort Study
Ahmed Bagit, Khalad Maliyar, Mark Mansour, et al.
Dermatology and Therapy
|
February 12, 2026
Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 Studies
Andrew Blauvelt, Leon Kircik, Eric L Simpson, et al.
Dermatology and Therapy
|
July 6, 2023
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
Kim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
Page
of 11